GRIGUOLO, GAIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.333
AS - Asia 1.692
EU - Europa 1.684
SA - Sud America 449
AF - Africa 334
OC - Oceania 30
Continente sconosciuto - Info sul continente non disponibili 17
Totale 8.539
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.116
SG - Singapore 607
DE - Germania 423
CN - Cina 353
IT - Italia 351
BR - Brasile 340
HK - Hong Kong 317
FI - Finlandia 248
PL - Polonia 72
SE - Svezia 64
GB - Regno Unito 61
NL - Olanda 57
FR - Francia 53
IN - India 51
RU - Federazione Russa 50
VN - Vietnam 46
AT - Austria 32
CA - Canada 28
AR - Argentina 23
CZ - Repubblica Ceca 23
CI - Costa d'Avorio 22
IQ - Iraq 20
JP - Giappone 20
TR - Turchia 20
IE - Irlanda 19
ES - Italia 18
ID - Indonesia 18
KR - Corea 18
PH - Filippine 17
EC - Ecuador 16
MA - Marocco 15
MX - Messico 15
AE - Emirati Arabi Uniti 14
BA - Bosnia-Erzegovina 14
EG - Egitto 14
GT - Guatemala 14
LC - Santa Lucia 14
ME - Montenegro 14
TN - Tunisia 14
BB - Barbados 13
AZ - Azerbaigian 12
BE - Belgio 12
BY - Bielorussia 12
CH - Svizzera 12
CR - Costa Rica 12
GN - Guinea 12
HR - Croazia 12
KE - Kenya 12
MK - Macedonia 12
SA - Arabia Saudita 12
UA - Ucraina 12
ZA - Sudafrica 12
ZW - Zimbabwe 12
DO - Repubblica Dominicana 11
JO - Giordania 11
LB - Libano 11
ML - Mali 11
PY - Paraguay 11
AU - Australia 10
BS - Bahamas 10
BZ - Belize 10
CO - Colombia 10
CY - Cipro 10
DZ - Algeria 10
IS - Islanda 10
JM - Giamaica 10
KZ - Kazakistan 10
MW - Malawi 10
MZ - Mozambico 10
UZ - Uzbekistan 10
BO - Bolivia 9
CW - ???statistics.table.value.countryCode.CW??? 9
GF - Guiana Francese 9
GM - Gambi 9
GR - Grecia 9
HN - Honduras 9
MD - Moldavia 9
NA - Namibia 9
PS - Palestinian Territory 9
RS - Serbia 9
TT - Trinidad e Tobago 9
VE - Venezuela 9
ET - Etiopia 8
LY - Libia 8
MG - Madagascar 8
MY - Malesia 8
NI - Nicaragua 8
NZ - Nuova Zelanda 8
PE - Perù 8
PK - Pakistan 8
PR - Porto Rico 8
TZ - Tanzania 8
UY - Uruguay 8
VC - Saint Vincent e Grenadine 8
XK - ???statistics.table.value.countryCode.XK??? 8
AO - Angola 7
BD - Bangladesh 7
BG - Bulgaria 7
BW - Botswana 7
CU - Cuba 7
Totale 8.222
Salva come PNG Salva come JPEG
Città #
Ashburn 697
Fairfield 574
Singapore 401
Chandler 384
Munich 330
Hong Kong 295
Woodbridge 275
Houston 223
Cambridge 213
Seattle 188
Helsinki 186
Ann Arbor 175
Wilmington 172
Beijing 118
Boardman 98
Padova 93
San Diego 73
Santa Clara 60
Medford 52
Princeton 52
Bytom 48
Des Moines 41
Los Angeles 39
Hefei 30
Roxbury 30
New York 28
London 27
Milan 27
São Paulo 27
Turku 26
Ho Chi Minh City 23
Nuremberg 23
Rome 22
Abidjan 21
Buffalo 21
Pune 19
Falls Church 16
Nanjing 16
Dublin 15
Dallas 14
Seoul 14
Tokyo 14
Bridgetown 13
Castries 13
Jyväskylä 13
Warsaw 13
Amsterdam 12
Conakry 12
Vienna 12
Amman 11
Bamako 11
Brooklyn 11
Chicago 11
Falkenstein 11
Guatemala City 11
Jinan 11
Podgorica 11
Rio de Janeiro 11
Zhengzhou 11
Baku 10
Harare 10
Kingston 10
Minsk 10
Nairobi 10
Nassau 10
Olomouc 10
Ottawa 10
Tashkent 10
Codogno 9
Jeddah 9
Lappeenranta 9
Reykjavik 9
Selvazzano Dentro 9
Shenyang 9
Skopje 9
Belo Horizonte 8
Cairo 8
Guangzhou 8
Hanoi 8
Managua 8
Maputo 8
Montreal 8
Phoenix 8
San José 8
Turin 8
Villafranca Padovana 8
Washington 8
Willemstad 8
Windhoek 8
Zagreb 8
Antananarivo 7
Baghdad 7
Banjul 7
Bishkek 7
Brussels 7
Cayenne 7
Dakar 7
Dar es Salaam 7
Kingstown 7
Luanda 7
Totale 5.741
Salva come PNG Salva come JPEG
Nome #
Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors 323
Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all? 299
ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis 266
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2 weeks letrozole: results of the PerELISA neoadjuvant study 218
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors 199
BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis 183
First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer 182
Androgen receptor expression and association with distant disease-free survival in triple negative breast cancer: Analysis of 263 patients treated with standard therapy for stage I-III disease 180
Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center 178
Immune characterization of breast cancer metastases: Prognostic implications 164
Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1–T3, N0–N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study 155
The immune system and hormone-receptor positive breast cancer: Is it really a dead end? 153
Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome 148
Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study 147
External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience 138
Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab. 134
Olaparib for the treatment of breast cancer 133
Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer 133
Evolution of HER2-low expression from primary to recurrent breast cancer 132
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade 131
Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology 128
Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I–III patients treated with standard therapy 128
Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value 123
Clinical applications of radiomics and deep learning in breast and lung cancer: A narrative literature review on current evidence and future perspectives 122
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 122
Fat grafting for breast cancer patients: From basic science to clinical studies 121
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 121
A comprehensive profiling of the immune microenvironment of breast cancer brain metastases 116
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 115
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1 115
Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy 114
Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy 113
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer 109
Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer 109
Gastric metastases of breast cancer: Histopathological and molecular characterization of a single Institution case series 108
Prognostic impact of proliferation for resected early stage ‘pure’ invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 106
A case of Hodgkin lymphoma in a patient with a history of bone pain and an initial diagnosis of chronic osteomyelitis 104
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer 104
The tumor microenvironment of primitive and metastatic breast cancer: Implications for novel therapeutic strategies 102
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment 101
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors 101
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis 99
Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial 99
Erbb2 mrna expression and response to ado-trastuzumab emtansine (T-dm1) in her2-positive breast cancer 97
A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer 93
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications 90
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer 88
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer 87
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype 86
Cardiac Safety of Adjuvant Trastuzumab and Paclitaxel for HER2+ early breast cancer patients published in Abstract Book of the 21th National Congress of Italian Association of Medical Oncology (AIOM) 25-27 October, 2019 - Rome, Italy Abstracts 84
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial 82
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation 82
Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival 80
Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast cancer 80
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade 78
Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability? 77
PI3K/PTEN/mTOR pathway dynamic tracking and prognostic value in HR+/HER2- BC patients with residual disease after neoadjuvant chemotherapy: a cohort study 75
Olaparib for advanced breast cancer 75
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 74
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials 73
Development of two machine learning models to predict conversion from primary HER2-0 breast cancer to HER2-low metastases: a proof-of-concept study 72
Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases 70
Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real-world data from a multicentric European cohort 69
Independent validation of the PAM50-based Chemo-Endocrine Score in hormonal receptor positive HER2-positive breast cancer treated with neoadjuvant therapy 69
Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer 65
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer 63
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer 59
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors 58
Radiological response of leptomeningeal metastases according to revised RANO criteria is associated with overall survival in breast cancer patients 58
Use of electronic administrative databases to measure quality indicators of breast cancer care: Experience of five regional oncology networks in Italy 58
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer 57
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases 56
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review 53
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial 50
Multidisciplinary management of HER2-positive breast cancer with brain metastases: An evidence-based pragmatic approach moving from pathophysiology to clinical data 50
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study 49
A systematic review of contemporary phase I trials in patients with lymphoma 48
Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials 45
The Impact of COVID-19 on Treatment Practices for Patients With Early Breast Cancer: A Cross-Sectional Study From a Large Cancer Center in Italy 38
BET inhibitors as potential anticancer agents 34
Gene expression profiling in a retrospective real-world cohort of breast cancer brain metastases and paired primary tumors identifies biological changes with potential therapeutic implications 5
Prognosis and biological characteristics of ER-low metastatic breast cancer: results from a multicenter cohort and the TONIC trial 3
Totale 8.706
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.577
article - articoli 32.577
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.154
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021716 0 0 32 51 40 137 35 57 97 142 96 29
2021/2022850 50 62 83 46 103 81 75 49 46 38 54 163
2022/2023742 122 93 40 106 76 80 26 47 93 10 41 8
2023/2024811 44 60 55 43 44 75 50 255 15 41 56 73
2024/20252.605 7 164 85 90 196 151 250 291 271 148 384 568
2025/20261.846 471 608 767 0 0 0 0 0 0 0 0 0
Totale 8.706